Perinatology.  2018 Jun;29(2):78-82. 10.14734/PN.2018.29.2.78.

Effectiveness of B-type Natriuretic Peptide in Caring for Preterm Infants

• Lee N
• Bae MH
• Han YM
• Park KH
• Byun SY

• KMID: 2468553
• DOI: http://doi.org/10.14734/PN.2018.29.2.78

Abstract

OBJECTIVE
Volume and pressure loading of the ventricles are associated with increased plasma B-type natriuretic peptide (BNP) levels. Hemodynamically significant patent ductus arteriosus (hsPDA) is a risk factor for life-threatening conditions in preterm infants. We compared follow-up data such as echocardiograms, BNP levels, comorbidities, and prognosis in preterm infants with PDA, and investigated the relationship between maternal prenatal factors and BNP.
METHODS
This single-center study performed between January 2015 and August 2016 included 63 preterm infants with a gestational age of < 35 weeks. We retrospectively evaluated the BNP levels on postnatal day 1, 3, and 7, clinical features, treatment method for PDA, mortality, and maternal prenatal factors.
RESULTS
Lower gestational age and smaller birth weight were associated with a higher incidence of hsPDA (P < 0.01). Postnatal day 3 BNP levels were significantly higher in the hsPDA group. BNP levels were not associated with failure of medication in the hsPDA group. Postnatal day 1 BNP levels were associated with an abnormal umbilical artery flow (P=0.017), and deceleration in fetal non-stress test result (P=0.01) but not with other maternal states.
CONCLUSION
BNP levels are a useful predictive biomarker for hsPDA in preterm infants during the 3rd days of life; however, they do not help in decision-making regarding treatment. BNP levels on the 1st postnatal day showed a positive correlation with prenatal factors such as abnormal umbilical artery flow and deceleration in fetal NST result.

Keyword

Brain natriuretic peptide; Patent ductus arteriosus; Premature infant

MeSH Terms

Birth Weight
Comorbidity
Deceleration
Ductus Arteriosus, Patent
Follow-Up Studies
Gestational Age
Humans
Incidence
Infant, Newborn
Infant, Premature*
Methods
Mortality
Natriuretic Peptide, Brain*
Plasma
Prognosis
Retrospective Studies
Risk Factors
Umbilical Arteries
Natriuretic Peptide, Brain

Reference

1). Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. Semin Perinatol. 1987. 11:64–71.

2). Kim JS., Shim EJ. B-type natriuretic peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants. Korean Circ J. 2012. 42:192–6.

3). Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988. 332:78–81.

4). Flynn PA., da Graca RL., Auld PA., Nesin M., Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr. 2005. 147:38–42.

5). Jameii Khosroshahi A., Kianfar A., Mohammadpour Aharanjani B., Sayad-pour Zanjani K. Usefulness of serum brain natriuretic peptide level for screening hemodynamically significant patent ductus arteriosus in preterm neonates. Iran J Pediatr. 2014. 24:766–9.

6). Lee HS., Choi WS., Choi BM., Lee KH., Eun BL., Yoo KH, et al. Usefulness of B-type natriuretic peptide assay in predicting symptomatic patent ductus arteriosus in preterm infants. J Korean Soc Neonatol. 2004. 11:44–53.

7). Choi BM., Lee KH., Eun BL., Yoo KH., Hong YS., Son CS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics. 2005. 115:e255–61.

8). Jeong HA., Shin J., Kim E., Lee EH., Choi BM., Son CS, et al. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. Korean J Pediatr. 2016. 59:183–9.

9). Maeda K. The development of late FHR deceleration and analysis of controversy FHR with hypoxia index. Res Rep Gynecol Obstet. 2017. 1:1–3.

10). Zhu R., Nie Z. A clinical study of the N-terminal pro-brain natriuretic peptide in myocardial injury after neonatal asphyxia. Pediatr Neonatol. 2016. 57:133–9.

11). Rasanen J., Debbs RH., Huhta JC. Echocardiography in intrauterine growth restriction. Clin Obstet Gynecol. 1997. 40:796–803.

12). Girsen A., Ala–Kopsala M., Mäkikallio K., Vuolteenaho O., Räsänen J. Cardiovascular hemodynamics and umbilical artery N–terminal peptide of proB–type natriuretic peptide in human fetuses with growth restriction. Ultrasound Obstet Gynecol. 2007. 29:296–303.

13). Tauber KA., Doyle R., Granina E., Munshi U. B–type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day. Acta Paediatr. 2016. 105:e352–5.

14). Moriichi A., Cho K., Mizushima M., Furuse Y., Akimoto T., Yamada T, et al. B–type natriuretic peptide levels at birth predict cardiac dysfunction in neonates. Pediatr Int. 2012. 54:89–93.